Application of diatomic iron-iron site nano-enzyme in preparation of targeted osteoarthritis treatment medicine by relieving oxidative stress and cartilage degeneration

By designing diatomic iron-iron site nanozymes, the problems of low catalytic efficiency and poor stability in existing technologies have been solved, achieving efficient ROS clearance and cartilage protection in osteoarthritis, and providing a new targeted treatment method for osteoarthritis.

CN121846307APending Publication Date: 2026-04-14SHANGHAI YANGZHI REHABILITATION HOSPITAL +1
0 Cites 2 Cited by

Patent Information

Application Number
CN202511787569.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-01
Publication Date
2026-04-14

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively mimic the multinuclear structure of natural antioxidant enzymes, resulting in low efficiency in catalyzing ROS. Furthermore, single-atom nanozymes are easily deactivated in biological environments, failing to effectively alleviate oxidative stress and cartilage degeneration in osteoarthritis.

Method used

We designed and synthesized diatomic iron-iron site nanozymes (Fe2-NCs). By embedding Fe-Fe dimers in nitrogen-doped porous carbon-anchored diatomic iron nanozyme catalysts, we utilized their nanoscale size and high specific surface area to enrich them in the joint cavity, mimicking the multi-enzyme catalytic activity of SOD, CAT, OXD, and GSH-Px, inhibiting NOX4 expression and pro-inflammatory mediators, and restoring mitochondrial function.

Benefits of technology

Fe2-NCs significantly improve catalytic activity and stability, enabling them to maintain efficient ROS scavenging in biological environments for extended periods, reduce oxidative stress, inhibit chondrocyte apoptosis and cartilage degeneration, and provide a novel targeted therapy for osteoarthritis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.
Need to check novelty before this filing date? Find Prior Art